- Matica Biotechnology has entered a non-exclusive strategic partnership with Cirsium Biosciences to support the development of plant-based AAV technology.
- The agreement positions Matica Bio as an early partner in Cirsium’s hybrid hub-and-spoke manufacturing model.
Matica Biotechnology, Inc. (Matica Bio), a CDMO specialising in viral vector production, has announced a non-exclusive strategic partnership with Cirsium Biosciences, a biotechnology company developing plant-based AAV technology. The collaboration was confirmed in a joint statement.
The partnership will see Matica Bio provide analytical and downstream support to complement Cirsium’s hybrid hub-and-spoke manufacturing model. This model integrates internal plant-based AAV production with external collaborators to improve flexibility, scalability, and distribution.
The companies said the initiative aims to address ongoing challenges in adeno-associated virus (AAV) manufacturing, where cost and efficiency remain barriers to gene therapy development and access. Their joint work is intended to support faster production cycles and broader patient availability.
Paul Kim, CEO of Matica Bio, said: “Partnering with Cirsium means working alongside a company committed to advancing innovation in gene therapy. We are proud to be an early partner in this decentralized model.”
Cirsium CEO Dr. Daniel Gibbs added that the collaboration would extend AAV manufacturing flexibility and scalability through its hub-and-spoke approach.
